Evidence map›Paper›PMID 40498093›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Overcoming resistance mechanisms in cancer immunotherapy-novel approaches and combinations.

Rahaman Shaik, Billa Yashaswi, Meravath Anjali, Sana Syeda, Huda Khan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rahaman ShaikDepartment of Pharmacology, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110062, India. shaikrahaman_sch@jamiahamdard.ac.in.
Billa YashaswiDepartment of Pharmacology, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad, 501510, Telangana, India.
Meravath AnjaliDepartment of Pharmacology, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad, 501510, Telangana, India.
Sana SyedaDepartment of Pharmacology, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad, 501510, Telangana, India.
Huda KhanDepartment of Pharmacology, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad, 501510, Telangana, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistance in cancer cells is a significant challenge for modern oncology, demanding the development of novel therapeutic techniques. This review examines new approaches to reducing drug resistance in cancer cells, with an emphasis on developing therapeutic options. Complex molecular findings into medication resistance in this article discuss genetic mutations, efflux pumps, altered signaling pathways, and micro environmental impacts. Targeted medicines, combination therapy, immunotherapies, and precision medicine methods are discussed as promising options. Combining standard cytotoxic medicines with molecularly targeted inhibitors results in synergistic effects. The routes used to avoid resistance are investigated. This article examines how immunotherapeutic approaches like immune checkpoint inhibitors and adoptive cell therapies can improve anti-tumor immune responses and overcome immune evasion mechanisms. Biomarker-driven techniques are crucial for predicting and monitoring therapy responses, leading to improved therapeutic results. This review examines the impact of medication resistance on cancer therapy paradigms and their potential future direction. Integrating developing therapeutic options can address problems and improve patient outcomes.

Indexed as

Antineoplastic AgentsDrug Resistance, NeoplasmImmunotherapyNeoplasmsAnimalsHumansImmune Checkpoint InhibitorsMolecular Targeted TherapyAntineoplastic AgentsImmune Checkpoint InhibitorsImmune checkpoint inhibitorsPrecision medicineResistanceTargeted therapeuticsTumor microenvironment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.